文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌淋巴结清扫及诱导化疗后同步放疗联合帕尼单抗治疗

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.
PubMed 文献 · J Urol · 2019-01-01

本前瞻性研究评估肌层浸润性膀胱癌患者在盆腔淋巴结清扫和铂类诱导化疗后,同步放疗联合帕尼单抗作为保膀胱治疗的安全性和疗效。31例开始治疗的患者中,16%出现3-4级毒性,94%达到完全缓解,中位随访34个月时10%接受挽救性膀胱切除术。结论认为该方案安全性非劣于历史顺铂/放疗对照,完全缓解率和保膀胱率令人鼓舞。

要点

  • 同步放疗联合帕尼单抗的3-4级毒性发生率为16%(95%CI 0-31),非劣于历史顺铂/放疗对照。
  • 31例可评估患者中29例(94%,95%CI 83-100)在3个月随访时达到完全缓解。
  • 中位随访34个月,4例局部复发,其中3例(10%)接受挽救性膀胱切除术。

核心结论

  • 盆腔淋巴结清扫和诱导化疗后同步放疗联合帕尼单抗的安全性非劣于历史顺铂/放疗对照。
  • 完全缓解率和保膀胱率较高,值得进一步研究。

研究设计与样本

  • 前瞻性研究,纳入cT1-4N0-2M0膀胱癌患者,计划样本量31例。
  • 主要终点为同步放疗联合帕尼单抗的毒性,与历史顺铂/放疗毒性率(3-5级毒性低于35%)比较。
  • 次要终点包括3个月随访完全缓解、保膀胱率、EGFR表达和RAS突变状态。

主要发现

  • 38例初始纳入患者中34例为cN0,盆腔淋巴结清扫后7例(21%)升期为pN+。
  • 38例中31例开始同步放疗联合帕尼单抗治疗。
  • 同步治疗期间5例(16%,95%CI 0-31)出现全身或局部3-4级毒性。
  • 4例因不良事件未完成治疗。
  • 31例中29例(94%,95%CI 83-100)达到完全缓解;中位随访34个月,4例局部复发,3例(10%)接受挽救性膀胱切除术。

临床怎么用

  • 对于肌层浸润性膀胱癌,盆腔淋巴结清扫和诱导化疗后同步放疗联合帕尼单抗可作为保膀胱治疗选择,安全性非劣于顺铂/放疗。
  • 治疗期间需监测3-4级毒性,本研究中4例因不良事件未完成治疗。
  • 完全缓解率和保膀胱率较高,但需进一步研究验证。

局限性

  • 研究为前瞻性单臂设计,主要终点与历史对照比较。
  • 计划样本量31例,实际初始纳入38例,开始同步治疗31例。
  • 中位随访34个月,局部复发和挽救性膀胱切除术数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this prospective study we evaluated the safety and efficacy of concurrent radiotherapy and panitumumab following neoadjuvant/induction chemotherapy and pelvic lymph node dissection as a bladder preserving therapy for invasive bladder cancer. MATERIALS AND METHODS: Patients with cT1-4N0-2M0 bladder cancer were treated with pelvic lymph node dissection and 4 cycles of platinum based induction chemotherapy followed by a 6½-week schedule of weekly panitumumab (2.5 mg/kg) and concurrent radiotherapy to the bladder (33 × 2 Gy). As the primary objective we compared concurrent radiotherapy and panitumumab toxicity to a historical control toxicity rate of concurrent cisplatin/radiotherapy (less than 35% of patients with Grade 3-5 toxicity). A sample size of 31 patients was estimated. Secondary end points included complete remission at 3-month followup, the bladder preservation rate, EGFR (epidermal growth factor receptor) expression and RAS mutational status. RESULTS: Of the 38 cases initially included in this study 34 were staged cN0. After pelvic lymph node dissection 7 cases (21%) were up staged to pN+. Of the 38 patients 31 started concurrent radiotherapy and panitumumab. During concurrent radiotherapy and panitumumab 5 patients (16%, 95% CI 0-31) experienced systemic or local grade 3-4 toxicity. Four patients did not complete treatment due to adverse events. Complete remission was achieved in 29 of 31 patients (94%, 95% CI 83-100). At a median followup of 34 months 4 patients had local recurrence, for which 3 (10%) underwent salvage cystectomy. Two tumors showed EGFR or RAS mutation while 84% showed positive EGFR expression. CONCLUSIONS: Concurrent radiotherapy and panitumumab following induction chemotherapy and pelvic lymph node dissection has a safety profile that is noninferior to the historical profile of concurrent cisplatin/radiotherapy. The high complete remission and bladder preservation rates are promising and warrant further study.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fransen van de Putte EE, Pos F, Doodeman B, et al. Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer. J Urol. 2019. PMID: 30321552. doi:10.1016/j.juro.2018.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。